60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
December 11, 2024 08:56 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals expands tafenoquine trial for babesiosis to Brigham and Women’s, targeting severe cases with unmet medical needs.
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
August 28, 2024 14:48 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals regains Nasdaq compliance after achieving a minimum closing bid price of $1.00 for 10 consecutive days.
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
August 14, 2024 11:01 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma Q2 2024 net product revenues doubled YoY to $125K, with an 18.3% sequential growth. Gross profit rose to $35K from a $124K loss.
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
August 06, 2024 09:26 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (NASDAQ: SXTP) announces a 1-for-12 reverse stock split, effective August 12, 2024 to meet Nasdaq’s $1.00 minimum bid price requirement.
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
May 02, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
SXTP received FDA comments on tafenoquine-babesiosis trial protocol; no major changes are needed. Trial planning and execution to proceed as planned.
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
March 14, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma advises of expected FDA response a month later than anticipated. Prepares for June 1, 2024, start of trial of tafenoquine for babesiosis.